These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 39048406)
1. Overview of the Role of Liquid Biopsy in Non-small Cell Lung Cancer (NSCLC). Ospina AV Clin Oncol (R Coll Radiol); 2024 Oct; 36(10):e371-e380. PubMed ID: 39048406 [TBL] [Abstract][Full Text] [Related]
2. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
3. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer. Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C Transl Res; 2024 Oct; 272():41-53. PubMed ID: 38838851 [TBL] [Abstract][Full Text] [Related]
4. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770 [TBL] [Abstract][Full Text] [Related]
5. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595 [TBL] [Abstract][Full Text] [Related]
6. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future. Scilla KA; Rolfo C Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467 [TBL] [Abstract][Full Text] [Related]
8. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related]
10. Red blood cells function as reservoirs of tumor DNA. Thompson JC; Li S; Jose JS; Predina J; Gupta A; Eruslanov E; Singhal S; Albelda SM; Mangalmurti NS Am J Physiol Lung Cell Mol Physiol; 2024 May; 326(5):L646-L650. PubMed ID: 38529551 [TBL] [Abstract][Full Text] [Related]
11. Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients. Gristina V; Russo TDB; Barraco N; Gottardo A; Pepe F; Russo G; Fulfaro F; Incorvaia L; Badalamenti G; Troncone G; Malapelle U; Russo A; Bazan V; Galvano A Sci Rep; 2024 Sep; 14(1):22141. PubMed ID: 39333636 [TBL] [Abstract][Full Text] [Related]
12. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. Esagian SM; Grigoriadou GΙ; Nikas IP; Boikou V; Sadow PM; Won JK; Economopoulos KP J Cancer Res Clin Oncol; 2020 Aug; 146(8):2051-2066. PubMed ID: 32462295 [TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing for tumor mutation quantification using liquid biopsies. Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650 [TBL] [Abstract][Full Text] [Related]
15. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Diao Z; Han Y; Zhang R; Li J Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer. Marinello A; Tagliamento M; Pagliaro A; Conci N; Cella E; Vasseur D; Remon J; Levy A; Dall'Olio FG; Besse B Cancer Treat Rev; 2024 Sep; 129():102791. PubMed ID: 38963991 [TBL] [Abstract][Full Text] [Related]
18. Understanding the Mechanisms of Resistance in Del Re M; Crucitta S; Gianfilippo G; Passaro A; Petrini I; Restante G; Michelucci A; Fogli S; de Marinis F; Porta C; Chella A; Danesi R Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416192 [TBL] [Abstract][Full Text] [Related]
19. The evolving role of liquid biopsy in lung cancer. Malapelle U; Pisapia P; Pepe F; Russo G; Buono M; Russo A; Gomez J; Khorshid O; Mack PC; Rolfo C; Troncone G Lung Cancer; 2022 Oct; 172():53-64. PubMed ID: 35998482 [TBL] [Abstract][Full Text] [Related]